@CaseyPutsch@WeWillBeFree24 Casey, I voted for you in the primary. I have followed you since your interview on tucker. You were treated unfairly. I do struggle with how you are going against the conservatives in the election. Getting liberals in office would be bad for ohio.
@BasedMikeLee@Eric_Schmitt An Ohio resident here. I contacted both Senator Marino and Senator Husted's office today and asked where they were on this. They have been a little quiet and I want to see their leadership on this important legislation. It's time to get it passed.
@BMcGrewvy Im a Catholic. I definitely have no problem criticizing public clergy especially when they act/speak in anti Christian manner. Not too happy with the pope right now.
$IBRX
To FDA Oncology @FDAOncology officials: ANKTIVA an IL-15 receptor agonist that stimulates NK cells, T cells, and memory T cells, has demonstrated a strong safety profile across 10+ years of clinical data—including long-term follow-up exceeding 47 months in key studies—with mostly mild-to-moderate, localized side effects consistent with BCG instillation itself and very low rates of severe (Grade 3/4) adverse events (around 0-3%).
It has been under investigation and development for over a decade, showing durable responses and high response rates in cancer patients.
While treatments like chemo and radiation—with their low success rates and significant risks of severe harm—are widely available, why limit or delay broader access to this safer, immune-boosting option? What is one substantive, evidence-based reason to restrict or delay patient access beyond standard regulatory and trial design considerations—particularly given the unnecessary seven-month delay in reviewing the sBLA for papillary disease, despite NCCN guidelines and consensus among urologists that CIS and papillary NMIBC originate from the same cancer-inducing clone and should be treated similarly?
To the FDA’s internal gatekeepers and longstanding reviewers who influence these decisions: Patients and families facing all types of cancer deserve timely access to therapies backed by strong safety and efficacy data. Lives are on the line. We respectfully ask for a clear response focused on patient outcomes, or an acknowledgment that the evidence supports accelerated and broader use.
One has to wonder whether higher government officials are aware of these access challenges and could help expedite solutions. @BladderCancerUS@LoriMills4CA42@FDA_KyleD
@doqholliday@thestoicplumber We are on the line between boomer and Gen X. Our motto is “ die with zero” we are giving our children and grandchildren funds when they need it. Now.